XAIR | Beyond AirĀ® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Oct.23, 2020 (GLOBE NEWSWIRE) — Beyond Air, Inc.(NASDAQ: XAIR ), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors and tumor metastases, […]